AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02312752 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intra-epidermal stimulation electrode
Description: A small piece of plastic with a tiny sharp protruding tip (the intra-epidermal stimulation electrode) will be applied to the foot and hand. Small sticker electrodes will be placed over nerves on the forearm or ankle. A stimulus will be applied to the electrode for intra-epidermal stimulation. The stimulus will be gradually increased from no stimulus to a stimulus that is barely felt as a pin-prick type of sensation. Thereafter, the stimulus will be applied 5-15 times per second for 10 periods of 40-60 seconds.
Study NCT02563340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BM-MSCs
Description: BM-MSCs are from third-party healthy donors, and have no HLA alleles similar to renal allograft donors or reacting to positive anti-HLA antibodies in recipients.
Study NCT02563340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Desensitization therapy (PP, IVIG, rituximab or Bortezomib)
Description: At least one drug or treatment is applied as desensitization therapy to decrease DSA, reduce B cells or inhibit plasma cells, depending on individual condition.
Study NCT02563340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Desensitization therapy (PP, IVIG, rituximab or Bortezomib)
Description: At least one drug or treatment is applied as desensitization therapy to decrease DSA, reduce B cells or inhibit plasma cells, depending on individual condition.
Study NCT02520024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-directed care
Study NCT04962269 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: monoexponential model, intravoxel incoherent motion (IVIM) model and stretched exponential model
Study NCT02657746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multi-component interventions
Description: The multi-component interventions (MCI) is comprised of all the following five components: 1) home health education (HHE) by government community health workers (CHWs), plus 2) blood pressure (BP) monitoring and stepped-up referral to a trained general practitioner (GP) using a checklist, plus 3) training public and private providers in management of hypertension and using a checklist, plus 4) designating hypertension triage counter and hypertension care coordinators in government clinics, plus 5) a financing model to compensate for additional health services and provide subsides to low income individuals with poorly controlled hypertension.
Study NCT00068770 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Radiation is standard treatment 6000cGy in 30 fractions. Patients will receive celecoxib 400 mg bid during RT treatment
Study NCT03870815 — intervention group
Intervention type: PROCEDURE
Intervention: CABG
Description: Patients who undergoing CABG
Study NCT03870815 — intervention group
Intervention type: PROCEDURE
Intervention: PCI
Description: Patients who undergoing PCI with DES
Study NCT05059392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training for Awareness, Resilience and Action (TARA)
Description: See arm description
Study NCT02629146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study NCT02629146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study NCT02629146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Study NCT02545907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Lyophilized carfilzomib for injection reconstituted with water to a final concentration of 2 mg/mL.
Study NCT02545907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 50mg capsule.
Study NCT02545907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 2mg tablet.
Study NCT02885363 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical examination
Study NCT02885363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical examination
Study NCT02885363 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Study NCT02885363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Study NCT02885363 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Study NCT02885363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Study NCT02336984 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2 pulsed DC1
Description: Vaccine administered weekly, with no more than 4 weeks delay over the course of 6 vaccines.
Study NCT02336984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: The loading dose of Trastuzumab will be 8 mg/kg and the maintenance dose given week 4 will be 6 mg/kg, both standard doses of trastuzumab.
Study NCT02336984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pertuzumab
Description: Pertuzumab 420 mg IV will be given at the same time as trastuzumab.
Study NCT03348267 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk protein isolate
Description: Milk protein isolate in a powder form consisted of 80% casein and 20% whey protein. 20g were diluted into 500 ml water
Study NCT03348267 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 500 mL drink that contained water (375 mL), sugar-free cordial (125 mL) and 2 g of low-calorie glucose/dextrose powder.
Study NCT00944775 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: 10-month exercise training program during hemodialysis sessions
Study NCT02453451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2D-/3D-TTE
Description: recording of 3 cardiac cycles
Study NCT02453451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D-TEE
Description: with colour-Doppler techniques for recording the ASD and the mitral valve
Study NCT02453451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking Test
Description: for 6 minutes
Study NCT02453451 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MitraClip procedure
Description: catheter-based non-surgical procedure in which the atrioventricular valves were stuck together permanently via a clip (during the regular patient care)
Study NCT04279444 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BKR-017
Description: BioKier, Inc. is developing colon-targeted, oral formulations of natural gut hormone secretagogues as non-prescription medical foods or supplements for nutritional use for improvement of insulin sensitivity.
Study NCT02293005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: 50 mg twice a day on Days 1-7 of each 21-day study cycle.
Study NCT02192450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart/glargine
Study NCT02192450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart/degludec
Study NCT02784314 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic-Assisted Radical Prostatectomy
Study NCT02784314 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Radical Prostatectomy
Study NCT01260610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: 300 mg of Tenofovir daily
Study NCT01260610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telbivudine
Description: 600 mg of Telbivudine daily
Study NCT01260610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir plus Telbivudine
Description: Tenofovir (300 mg daily) plus Telbivudine (600 mg daily)
Study NCT04381104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: The intervention arm will receive 2 capsules of paracetamols of 500mg.
Study NCT04381104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracetamol
Description: The intervention arm will receive 2 capsules of paracetamols of 500mg.
Study NCT02564471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: FDA approve dosing schedule
Study NCT02564471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone and Proguanil
Description: FDA approve dosing schedule
Study NCT02564471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: FDA approve dosing schedule
Study NCT02564471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies Vaccine
Description: FDA approve dosing schedule
Study NCT02564471 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies Vaccine
Description: FDA approve dosing schedule
Study NCT00941733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IN.PACT Amphirion
Description: Balloon Angioplasty
Study NCT00068770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Celecoxib will begin 1 week prior to RT at 400mg bid orally. One day 1 only 1 dose will be administered. Starting on day 2 and throughout treatment until progression, 2 doses will be administered at least 12 hours apart. Celecoxib will continue throughout the 6 week course of RT.
Study NCT00941733 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PTA
Description: Balloon Angioplasty
Study NCT03614026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teachers and Parents as Partners
Description: Family-school partnership intervention
Study NCT04183400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Awareness For Empowerment (SAFE)
Description: SAFE is a mindfulness-based cognitive-behavioral intervention that aims to build risk-related attention skills.
Study NCT00809289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esreboxetine
Description: Once daily administration of 4mg esreboxetine for 3 days, followed by 8mg esreboxetine for 3 days, followed by 10mg esreboxetine for 3 days. Drug will be administered double-blind.
Study NCT00809289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Once daily administration of placebo for 9 days. Placebo will be administered double blind
Study NCT00809289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: Once daily administration of placebo for 8 days followed by open label single oral dose of 400mg moxifloxacin on day 9
Study NCT01677195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACCS100
Description: ACCS100 is not absorbed. The dose is estimated based on the volume of the gastrointestinal tract. We estimate that the average human intestinal tract has a volume of approximately 4 liters. In the high dose group, the effective concentration in the gut is 0.75 milligrams per milliliter. In the low dose, the effective concentration in the gut is 0.375 milligrams per milliliter. The test article is made by filling gelatin capsules with 500 milligrams of ACCS100. There are no excipients used in the manufacturing process of the test article.
Study NCT01677195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is calcium carbonate, USP. This calcium mineral does not absorb mycotoxins, specifically aflatoxin and fumonisin. This mineral has approximately the same physical appearance as active test article.
Study NCT01519518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: unfractionated heparin
Description: 70 units/kg body weight intravenous
Study NCT01519518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bivalirudin
Description: intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
Study NCT02843789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Study NCT04691479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview (MI) & Adherence Follow-Up
Description: 1. MEntA: Educational \& Training Program~2. Stratification: Identification of Personal Variables (Age, Level of study, Work status, preference of care attention, digital behaviour)~3. Adherence evaluation: Evaluation of Perceived Competence, Quality of Life, Mood, Activities, Social relations and Social Support~4. Identification of Care plan and Schedule next visits~5. Follow-up D30-D60-D90-D180 depending of the care plan, through the channel that belong for each care plan
Study NCT04691479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Follow-Up
Description: The nurse takes the compliance of the CPAP device, and ask to the patient if he had some problems.
Study NCT01176591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo session 1, Aprepitant session 2
Description: placebo in session 1, Aprepitant 80 mg in session 2, oral administration.
Study NCT01176591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo session 1, Placebo session 2
Description: Placebo, one per session, oral administration
Study NCT01626365 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-thermosoftening
Description: Intubation is performed with a double-lumen tube put into normal saline at room temperature.
Study NCT01626365 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thermosoftening
Description: Intubation is performed with a double lumen tube put into warm normal saline (40°C).
Study NCT01151553 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CRT Therapy
Description: Screen for enrollment criteria, consented, echocardiogram and electrocardiogram performed, demographics reviewed, obtain blood sample, pre-operative QOL questionnaire and 6 minute hall walk
Study NCT02497326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyfax & Lignocain gel or silvazine cream
Description: olyfax skin ointment plus Lignocain gel will be applied on superficial PTB area and silver sulphadiazine cream on deep PTB in morning and evening after wound wash.
Study NCT02497326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Heparin
Description: Heparin solution (5000 IU/ml) will be sprinkled aseptically on burn surface twice a day for the first 2 days, by #27 needle connected via drip set to the drip containing heparin aqueous saline. The dose will be reduced to 75% of day 1 on day 3 and 4 and to 50% on day 5. Administration of heparin saline solution will be in 3 cycles with 5-10 minutes interval
Study NCT02497326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: IV Analgesic ( Inj. Tramadol 10mg/dose) will only be given to the patients (in both groups) having pain score >4, assessed 3 times a day by Numeric Visual Analogue scale (NVAS).
Study NCT02497326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: IV Analgesic ( Inj. Tramadol 10mg/dose) will only be given to the patients (in both groups) having pain score >4, assessed 3 times a day by Numeric Visual Analogue scale (NVAS).
Study NCT01266772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast sodium.
Description: Children with asthma treated with montelukast and budesonide.
Study NCT01266772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet and budesonide
Description: Children with asthma treated with placebo tablet and budesonide.
Study NCT01221441 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TissueGene-C
Description: Single intraarticular injection at 3 x 10e7 cells
Study NCT01221441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Single intraarticular injection of normal saline as a placebo control
Study NCT01138124 — intervention group
Intervention type: DRUG
Intervention: Gabapentin prescriptions
Description: The exposure of interest is gabapentin use as defined by prescriptions recorded by the GPRD general practitioner (British National Formulary codes). Data on prescriptions for gabapentin will be extracted for each case and control from entry into the study cohort up to the index date (the exposure window). Gabapentin exposure will be parameterized as follows: (1) Ever versus never exposed; (2) Number of prescriptions; (3) Duration of exposure; and (4) Cumulative dose. These parameterizations will also be examined with a 2 year lag time from the index date, limiting the exposure window from entry into the study cohort up to 2 years prior to the index date.
Study NCT01296269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: one-time intranasal administration, 24 International Units, 5 puffs for each nostril
Study NCT01296269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine Vasopressin
Description: one-time intranasal administration, 20 International Units, 5 puffs in each nostril
Study NCT01296269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: contains all the ingredients as in the oxytocin and vasopressin conditions, save for the active ingredient, one time intranasal administration, 5 puffs in each nostril
Study NCT04395040 — intervention group
Intervention type: OTHER
Intervention: Semi-structured interview
Description: Semi-structured interview
Study NCT03003793 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hyperinsulinemic euglycemic clamp
Description: Hyperinsulinemic euglycemic clamp to detect insulin sensitivity
Study NCT02395601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-1205
Description: Small molecule inhibitor of the enzyme EZH2
Study NCT00997269 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Co-enzyme Q-10
Description: Patients will be supplemented with 300 mg of CoQ-10 1 time daily for one month
Study NCT00997269 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be supplemented with CoQ-10 placebo 1 time daily for one month
Study NCT00683046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3,.
Study NCT00683046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 140 mg/m2 IV on day -2.
Study NCT00683046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stem cells
Description: Stem cell infusion on day 0.
Study NCT00683046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath
Description: Campath, 20 mg IV on day -7, 6, -5, -4, and -3.
Study NCT03974607 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Program (PAP)
Description: A Physical Activity Program (PAP) will be carried out. Previously an initial measure will be made to know the little active adolescents. At the end of the PAF a retention measure will be carried out to know the scope and persistence of the variables analyzed. The PAF will be developed with a frequency of three weekly sessions, of 60 minutes, in the period of the intervention, with the exception of weeks in which there is a public holiday, where we will take measures to recover the class. A schedule for the sessions will be set according to the interests of the participants and will be the same for all. During the sessions, basic physical abilities and motor skills will be worked on with playful proposals focused on the improvement of physical and psychosocial parameters. They will always have the same monitor Graduate in Physical Activity and Sports Sciences, which will be responsible for developing the PAF.
Study NCT02629627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Conjugated linoleic acid/Leucine
Description: Conjugated linoleic acid/Leucine capsules, 825mg time daily with the first bite of eat meal during 12 weeks.
Study NCT02629627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid/Leucine
Description: Conjugated linoleic acid/Leucine capsules, 825mg time daily with the first bite of eat meal during 12 weeks.
Study NCT02629627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin in a dosis of 500mg per day (with the first bite of the second meal) during 12 weeks
Study NCT02629627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin in a dosis of 500mg per day (with the first bite of the second meal) during 12 weeks
Study NCT02629627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of ACL/Leucine
Description: Homologate placebo of ACL/Leucine (linseed oil capsules) in a dosis of 3600 mg each 24 hrs (2 capsules of 2400 mg with the first meal and 1200 mg or 1 capsule with the second meal) during 12 weeks.
Study NCT02629627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of ACL/Leucine
Description: Homologate placebo of ACL/Leucine (linseed oil capsules) in a dosis of 3600 mg each 24 hrs (2 capsules of 2400 mg with the first meal and 1200 mg or 1 capsule with the second meal) during 12 weeks.
Study NCT02629627 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Metformin
Description: homologate placebo of metformin (calcinated magnesia) in a dosis of 500 mg per day (with the first bite of the second meal) during 8 weeks
Study NCT00134277 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Infragenual dilatation
Description: Infragenual dilatation